Abstract
Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.
Original language | English (US) |
---|---|
Pages (from-to) | 167-170 |
Number of pages | 4 |
Journal | Unknown Journal |
Volume | 6 |
Issue number | 2 |
DOIs | |
State | Published - 1983 |
ASJC Scopus subject areas
- Oncology
- Cancer Research